It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Home > Mechanism of Action

JAKAVI is a potent JAK1 and JAK2 inhibitor

  • JAKAVI acts on both JAK1 and JAK2 to inhibit overactive JAK/STAT signalling in MF[1]
  • JAKAVI binds to the kinase domain of JAK1 and JAK2 and inhibits JAK1 and JAK2 signalling regardless of the JAK2V617F mutation status[1]
  • JAKAVI inhibits JAK stimulation of STAT and downstream effects on cellular proliferation[1]

Hydroxyurea is a cytoreductive therapy and does not alter the natural history of the disease[2]


 

Explore common prognoses for patients with MF
See the safety data from JAKAVI clinical trials
Learn more about customisable dosing options for your patients

References

  1. JAKAVI® (ruxolitinib) tablets: EU Summary of Product Characteristics. Novartis; January 2022.

  2. Mughal T, Vaddi K, Sarlis NJ, Verstovsek S. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014;7:89-101.

     

This is an international website for JAKAVI® (ruxolitinib) and is intended for healthcare professionals outside of the United States. If you are a U.S. resident, please click here or on the U.S. Residents link on this page.

© 2024 Novartis Pharma AG. All rights reserved.
117343-2 6/22
Use of this website is subject to our Terms of Use.